Physician profile
Iris Lee
NPI 1881911667
$6,020.79
in general payments reported to CMS, 2019-2025
32 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $457 · 2021: $894 · 2022: $893 · 2023: $1,019 · 2024: $1,695 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787 · Education: $65.30 · Travel and Lodging: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.09 |
| Education | $65.30 |
| Travel and Lodging | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,960.42 | 2019-2025 | Exalt Model D, Spyglass, Acquire |
| Abbvie INC. | $901.89 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $520.05 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $440.84 | 2020-2024 | Stelara, Tremfya, Remicade |
| Celgene Corporation | $318.10 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.44 | 2021-2024 | Xifaxan |
| Gilead Sciences, INC. | $247.28 | 2019-2024 | |
| Pfizer INC. | $245.69 | 2019-2024 | |
| Qol Medical, LLC | $162.77 | 2019-2023 | Sucraid |
| Echosens North America, INC. | $111.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $104.67 | 2021 | |
| Phathom Pharmaceuticals, INC. | $79.74 | 2024 | Voquezna |
| Abiomed | $79.39 | 2024 | Impella |
| Ferring Pharmaceuticals INC. | $73.43 | 2019-2023 | Rebyota |
| Celltrion USA INC. | $65.30 | 2024 | Zymfentra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $53.29 | 2022 | |
| Intercept Pharmaceuticals, INC. | $46.86 | 2022-2023 | Ocaliva |
| Olympus America INC. | $44.59 | 2022-2023 | Endoclot Phs, Disposable Grasping Forceps, Hanarostent Lowaxtm Duodenum/Pylorus(Nnn) |
| Ardelyx, INC. | $42.80 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $37.44 | 2019-2023 | Dificid |
| Amgen INC. | $33.10 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.85 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $22.64 | 2023 | Sutab |
| Lilly USA, LLC | $22.48 | 2023 | |
| Albireo Pharma, INC. | $20.94 | 2023 | Bylvay |
| Daiichi Sankyo INC. | $20.64 | 2020 | |
| Ucb, INC. | $19.38 | 2019 | |
| Ambu INC. | $18.08 | 2020 | |
| Endogastric Solutions, INC | $17.04 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.69 | 2022 | |
| W. L. Gore & Associates, INC. | $11.83 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.